FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1806977823> ?p ?o ?g. }

• W1806977823 endingPage "9" @default.
• W1806977823 startingPage "1301" @default.
• W1806977823 abstract "The Medical Research Council of Canada has initiated human growth hormone (hGH) therapy in 151 patients with documented complete hGH deficiency that was idiopathic in 76% of cases, secondary to craniopharyngioma (organic) in 17% and of varied cause in 7%. Approximately 50% of the patients with idiopathic disease had isolated hGH deficiency; during therapy thyroid deficiency developed in five patients and cortisol deficiency in three. A similar increase in mean height velocity occurred in the first treatment phase for patients less than 12 years old (0.93 plus or minus 0.30 cm/mo) and those 12 years and older (0.86 plus or minus 0.29 cm/mo). Although subsequent courses of hGH therapy yielded significantly diminished response in both age groups, this diminution was not progressive: the height velocity of the younger patients returned to 0.82 plus or minus 0.26 cm/ml in the fifth therapy phase. The mean height velocity attained at the optimal dosage (0.20 to 0.29 units/kg three times per week) for each age group did not differ significantly. Despite therapy being carried out for only 6 months of the year, normal increment ratios for height age and bone age against chronologic age were observed in the patients with idiopathic disease. In only four patients did treatment failure occur, and three of these were more than 20 years old. The addition of fluoxymesterone (10 mg/d) to the hGH therapeutic regimen (15 units/wk), when diminished response to hGH alone became evident, promoted an enhanced growth response in 9 of 11 older patients. These data indicate that age of the patient and dosage of hGH, but not diagnostic category, were important influences on the response to therapy. Younger patients responded best and maintained a higher mean growth velocity than older patients during intermittent hGH therapy" @default.
• W1806977823 created "2016-06-24" @default.
• W1806977823 creator A5010812709 @default.
• W1806977823 creator A5025297714 @default.
• W1806977823 creator A5062737897 @default.
• W1806977823 creator A5080713787 @default.
• W1806977823 creator A5083229654 @default.
• W1806977823 date "1975-06-07" @default.
• W1806977823 modified "2023-10-18" @default.
• W1806977823 title "Medical Research Council of Canada therapeutic trial of human growth hormone: first 5 years of therapy." @default.
• W1806977823 cites W1509144404 @default.
• W1806977823 cites W1565870791 @default.
• W1806977823 cites W1968522047 @default.
• W1806977823 cites W1971310154 @default.
• W1806977823 cites W1978196119 @default.
• W1806977823 cites W1980949441 @default.
• W1806977823 cites W1982317195 @default.
• W1806977823 cites W1989184098 @default.
• W1806977823 cites W1995647972 @default.
• W1806977823 cites W1998106769 @default.
• W1806977823 cites W2001536155 @default.
• W1806977823 cites W2029148734 @default.
• W1806977823 cites W2041044880 @default.
• W1806977823 cites W2053105417 @default.
• W1806977823 cites W2060950552 @default.
• W1806977823 cites W2069176146 @default.
• W1806977823 cites W2081307174 @default.
• W1806977823 cites W2083467422 @default.
• W1806977823 cites W2085823953 @default.
• W1806977823 cites W2086390579 @default.
• W1806977823 cites W2092530075 @default.
• W1806977823 cites W2094826933 @default.
• W1806977823 cites W2106290045 @default.
• W1806977823 cites W2110689139 @default.
• W1806977823 cites W2140615022 @default.
• W1806977823 cites W2171589158 @default.
• W1806977823 cites W2395737280 @default.
• W1806977823 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1956139" @default.
• W1806977823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/165002" @default.
• W1806977823 hasPublicationYear "1975" @default.
• W1806977823 type Work @default.
• W1806977823 sameAs 1806977823 @default.
• W1806977823 citedByCount "23" @default.
• W1806977823 countsByYear W18069778232018 @default.
• W1806977823 crossrefType "journal-article" @default.
• W1806977823 hasAuthorship W1806977823A5010812709 @default.
• W1806977823 hasAuthorship W1806977823A5025297714 @default.
• W1806977823 hasAuthorship W1806977823A5062737897 @default.
• W1806977823 hasAuthorship W1806977823A5080713787 @default.
• W1806977823 hasAuthorship W1806977823A5083229654 @default.
• W1806977823 hasConcept C126322002 @default.
• W1806977823 hasConcept C187212893 @default.
• W1806977823 hasConcept C2781413609 @default.
• W1806977823 hasConcept C2991696056 @default.
• W1806977823 hasConcept C71924100 @default.
• W1806977823 hasConcept C89551170 @default.
• W1806977823 hasConcept C90924648 @default.
• W1806977823 hasConceptScore W1806977823C126322002 @default.
• W1806977823 hasConceptScore W1806977823C187212893 @default.
• W1806977823 hasConceptScore W1806977823C2781413609 @default.
• W1806977823 hasConceptScore W1806977823C2991696056 @default.
• W1806977823 hasConceptScore W1806977823C71924100 @default.
• W1806977823 hasConceptScore W1806977823C89551170 @default.
• W1806977823 hasConceptScore W1806977823C90924648 @default.
• W1806977823 hasIssue "11" @default.
• W1806977823 hasLocation W18069778231 @default.
• W1806977823 hasOpenAccess W1806977823 @default.
• W1806977823 hasPrimaryLocation W18069778231 @default.
• W1806977823 hasRelatedWork W1510870701 @default.
• W1806977823 hasRelatedWork W1986489121 @default.
• W1806977823 hasRelatedWork W1991398866 @default.
• W1806977823 hasRelatedWork W2019020403 @default.
• W1806977823 hasRelatedWork W2029641788 @default.
• W1806977823 hasRelatedWork W2091726406 @default.
• W1806977823 hasRelatedWork W2144189739 @default.
• W1806977823 hasRelatedWork W2416473018 @default.
• W1806977823 hasRelatedWork W2590249073 @default.
• W1806977823 hasRelatedWork W4242643752 @default.
• W1806977823 hasVolume "112" @default.
• W1806977823 isParatext "false" @default.
• W1806977823 isRetracted "false" @default.
• W1806977823 magId "1806977823" @default.
• W1806977823 workType "article" @default.